
On Tuesday, Valneva SE (NASDAQ:VALN) revealed antibody persistence data three years after vaccination with a single dose of its chikungunya vaccine IXCHIQ.
The results align with Valneva’s expectations for this vaccine, confirming a strong and long-lasting antibody persistence across all age groups investigated.